| abstract |
The present invention provides a compound represented by the general formula (I) or pharmacologically acceptable salts thereof, [in formula, A represents C3 to C12 cycloalkyl group optionally substituted by 1 to 3 substituents selected from fluoro group, hydroxyl group, C1 to C6 alkyl and the like; R1, R2 and R3 respectively and independently represent hydrogen, fluoro group or C1 to C6 alkyl; R4 represents hydrogen or prodrug group; Y represents -CH2-CHR5-CH2-NHR6 (wherein, R5 represents hydrogen, C1 to C6 alkyl or C1 to C6 alkoxy group; R6 represents hydrogen or prodrug group.)]. The compound has the inhibition activity to TAFIa enzyme and is useful as a therapeutic agent for cardiac infarction, stenocardia, acute coronary syndrome, brain infarction, deep vein thrombosis, pulmonary embolism and the like. |